.jpg?format=webp&width=780)
A groundbreaking 12-week study reveals the effectiveness and safety of the Avation device, the first closed-loop wearable therapy for bladder control. In a multicenter trial with 96 participants, the novel neuromodulation system demonstrated significant reductions in bladder issues, surpassing minimal clinically important differences in quality of life indicators. Long-term results at 12 months remained robust, with a favorable safety profile, 88.5% compliance, and high patient satisfaction. This non-invasive, patient-centered alternative marks a significant advancement in overactive bladder treatment.
Like
Save
Share